Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
[2,4,5,2',4',5'-hexachlorobiphenyl co-treated with 3,4,5,3',4'-pentachlorobiphenyl] results in increased activity of CYP1A2 protein; [3,4,5,3',4'-pentachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl] results in increased activity of CYP1A2 protein
2,4,5,2',4',5'-hexachlorobiphenyl promotes the reaction [AHR protein results in increased expression of CYP1A2]; [3,4,3',4'-tetrachlorobiphenyl co-treated with 3,4,5,3',4'-pentachlorobiphenyl co-treated with 3,4,5,3',4',5'-hexachlorobiphenyl co-treated with 2,3,3',4,4'-pentachlorobiphenyl co-treated with 2,3',4,4',5-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] promotes the reaction [AHR protein results in increased expression of CYP1A2 mRNA]; [AHR protein co-treated with CYP1A2 protein] affects the susceptibility to [3,4,3',4'-tetrachlorobiphenyl co-treated with 3,4,5,3',4'-pentachlorobiphenyl co-treated with 3,4,5,3',4',5'-hexachlorobiphenyl co-treated with 2,3,3',4,4'-pentachlorobiphenyl co-treated with 2,3',4,4',5-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180]; [Tetrachlorodibenzodioxin co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with Diethylhexyl Phthalate co-treated with bisphenol A] results in decreased expression of CYP1A2 mRNA
